Vantive Launches as Independent Vital Organ Therapy Company to Transform Kidney Care Worldwide

Vantive: A New Era in Renal Therapy

On February 3, 2025, a significant transformation took place in the world of renal care with the launch of Vantive, a new independent company that specializes in therapies for vital organs. Formerly part of Baxter's kidney care division, Vantive is now backed by a global investment firm, Carlyle. With 70 years of pioneering innovation in renal treatment, Vantive is poised to extend lives and broaden the possibilities for patients and healthcare teams worldwide.

The driving mission behind Vantive is clear: to enhance renal therapy standards and improve the quality of life for approximately 4 million people currently receiving dialysis treatment for chronic kidney disease. The company's focus is not only on the technical aspects of treatment but also on alleviating the physical and emotional burdens faced by patients during their therapeutic journeys.

Empowering Patients and Healthcare Professionals
Vantive recognizes that timely access to appropriate therapy is crucial for patients initiating dialysis treatment. Chris Toth, CEO of Vantive, emphasizes the company’s goal of better equipping patients and healthcare professionals during these critical moments. The vision is to offer improved options, greater control, and enhanced opportunities, all aimed at transforming how renal therapies are administered and experienced.

As a new standalone entity, Vantive aims to break down barriers that hinder the initiation and maintenance of vital organ therapies. The company leverages its established legacy to enhance renal care solutions, proving to be a game-changer for healthcare professionals and patients alike.

Innovative Solutions for Better Outcomes
Vantive introduces a robust suite of innovative products, advanced digital solutions, and state-of-the-art services. These offerings cater to both home and clinical dialysis, in addition to critical care therapies designed to support renal and other vital organ functions in intensive care settings. The engagement of patients with Vantive’s solutions has surpassed a staggering one million daily interactions across over 100 countries, opening doors to continuous improvement.

One prime example of Vantive's dedication to patient-centric solutions is its remote patient monitoring technology. Research has highlighted that this innovation correlates with reduced mortality rates, fewer hospital admissions, and improved treatment adherence, culminating in enhanced patient experiences and outcomes. This integrated approach illustrates Vantive’s commitment to advancing kidney care and organ therapies beyond traditional norms.

Leadership and Vision for Future Innovation
Kieran Gallahue, Chair of Vantive’s Board, expressed excitement regarding the company’s potential to elevate the entire renal care landscape. With Vantive positioned to enhance connectivity, transparency, and access to critical information throughout the care continuum, there are profound opportunities for improving both patient and caregiver experiences. Under Gallahue's leadership, the company aims to champion the mission of extending lives and creating new possibilities for patients universally.

Robert Schmidt, Co-Global Head of Carlyle's healthcare sector, echoed this sentiment, highlighting the company’s long-term vision to augment Vantive’s global impact. The partnership emphasizes an unwavering commitment to innovation that enhances care access and quality while optimizing healthcare professional efficiency.

As Alexandre Pexioto, General Manager for Southern Latin America at Vantive, articulated, the company is embarking on a new era of leadership in renal care, empowered by Carlyle's support. The team is energized by the prospect of fundamentally transforming therapies and enhancing patient experiences through innovative, high-quality solutions that create new opportunities.

About Vantive
Vantive stands out as a trailblazer in vital organ therapies, driven by the mission to extend lives and enhance opportunities for both patients and healthcare providers worldwide. With a legacy of 70 years in renal innovation, Vantive is committed to improving dialysis experiences through advanced digital solutions and services. Their vision extends beyond kidney care, as they invest in evolving therapies for vital organs. Ultimately, Vantive strives to offer greater flexibility for healthcare delivery, fostering longer, healthier lives for patients.

For more information, interested parties can visit Vantive's website and connect with the company through their social media platforms.

Sources: Jager KJ et al., Kidney Int. 2019; Paniagua R et al., Nephrol Dial Transplant.